Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Beleave Provides Update on Manitoba Retail Licensing Agreement

Posted on: 01 Mar 18

TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE); (OTCQX:BLEVF) would like to provide an update with regard to recent retail licensing grants in the province of Manitoba.  On January 3rd, 2018 the Company announced that it had signed a letter of intent with Seven Oaks of Manitoba to supply 1.25 million grams of dry cannabis flower or equivalent.  The transaction was contingent on Seven Oaks’ ability to obtain a retail license from the government of Manitoba, however they did not obtain it in this round of licensing.   

“We maintain that Seven Oaks would have been a great choice retail partner for us in Manitoba but understand licenses were limited and the environment highly competitive,” commented Beleave Chief Executive Officer Andrew Wnek. “The team is actively exploring partnership opportunities in all provinces and will continue to do so in Manitoba and stand behind Seven Oaks as they further explore other distribution and retail prospects.”

In addition the company would like to congratulate the four companies that were chosen to open Manitoba’s retail distribution locations.

About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

For further information please contact:

Sebastian de Kloet
Phone: (905) 979 - 5173 

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on


Last updated on: 02/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.